Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.
If there are silver linings to COVID-19, they can be seen in part by the stunning technological advancements and rapid adoption that we are witnessing in diagnostic and prognostic medicine—in particular, the field of respiratory connected devices, where exciting innovation abounds. These advancements seek to produce better outcomes, greater patient centricity, and deliver high quality, continuous data with new and important endpoints. Read this White Paper written by IQVIA Connected Devices leaders Dr Tapan Raval and Mike Bruhns to learn more.
Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.